| Authors: |
Thompson EW; School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia. e2.thompson@qut.edu.au.; Translational Research Institute, Woolloongabba, Queensland, Australia. e2.thompson@qut.edu.au., Redfern AD; UWA Medical School, University of Western Australia, Crawley, Western Australia, Australia., Brabletz S; Department of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany., Berx G; Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium., Agarwal V; UWA Medical School, University of Western Australia, Crawley, Western Australia, Australia., Ganesh K; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Huang RY; School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan., Ishay-Ronen D; Oncology Institute, Shaba Medical Center, Ramat-Gan, Israel., Savagner P; INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculty of Medicine, University Paris-Saclay, Villejuif, France., Sheng G; International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan., Stemmler MP; Department of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany., Brabletz T; Department of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany. thomas.brabletz@fau.de.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Bavarian Cancer Research Center (BZKF), Erlangen, Germany. thomas.brabletz@fau.de. |
